



A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

NAME : Mrs. RIYA GOEL

AGE/ GENDER : 27 YRS/FEMALE **PATIENT ID** : 1678192

COLLECTED BY REG. NO./LAB NO. : 122411210016

REFERRED BY **REGISTRATION DATE** : 21/Nov/2024 02:20 PM BARCODE NO. : 12505769 **COLLECTION DATE** : 21/Nov/2024 03:14PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 21/Nov/2024 04:22PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Value Unit **Biological Reference interval Test Name**

HAEMATOLOGY HAEMOGLOBIN (HB)

HAEMOGLOBIN (HB) 12.0 - 16.0 11.6^{L} gm/dL

by CALORIMETRIC

INTERPRETATION:-Hemoglobin is the protein molecule in red blood cells that carries oxygen from the lungs to the bodys tissues and returns carbon dioxide from the tissues back to the lungs.

A low hemoglobin level is referred to as ANEMIA or low red blood count.

ANEMIA (DECRESED HAEMOGLOBIN):

1) Loss of blood (traumatic injury, surgery, bleeding, colon cancer or stomach ulcer)

2) Nutritional deficiency (iron, vitamin B12, folate)

3) Bone marrow problems (replacement of bone marrow by cancer)

4) Suppression by red blood cell synthesis by chemotherapy drugs

5) Kidney failure

6) Abnormal hemoglobin structure (sickle cell anemia or thalassemia).

POLYCYTHEMIA (INCREASED HAEMOGLOBIN):

- 1) People in higher altitudes (Physiological)
- 2) Smoking (Secondary Polycythemia)
- 3) Dehydration produces a falsely rise in hemoglobin due to increased haemoconcentration
- 4) Advanced lung disease (for example, emphysema)
- 5) Certain tumors
- 6) A disorder of the bone marrow known as polycythemia rubra vera,
- 7) Abuse of the drug erythropoetin (Epogen) by athletes for blood doping purposes (increasing the amount of oxygen available to the body by chemically raising the production of red blood cells).

NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)





A PIONEER DIAGNOSTIC CENTRE

NAME : Mrs. RIYA GOEL

AGE/ GENDER : 27 YRS/FEMALE **PATIENT ID** : 1678192

COLLECTED BY REG. NO./LAB NO. : 122411210016

REFERRED BY **REGISTRATION DATE** : 21/Nov/2024 02:20 PM BARCODE NO. : 12505769 **COLLECTION DATE** : 21/Nov/2024 03:14PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 21/Nov/2024 05:22PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Value Unit **Biological Reference interval Test Name**

ENDOCRINOLOGY THYROID STIMULATING HORMONE (TSH)

THYROID STIMULATING HORMONE (TSH): SERUM 1.767 μIU/mL 0.35 - 5.50

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

3rd GENERATION, ULTRASENSITIVE

INTERPRETATION:

AGE	REFFERENCE RANGE (μIU/mL)
0 – 5 DAYS	0.70 - 15.20
6 Days – 2 Months	0.70 – 11.00
3 – 11 Months	0.70 - 8.40
1 – 5 Years	0.70 – 7.00
6 – 10 Years	0.60 - 5.50
11 - 15	0.50 - 5.50
> 20 Years (Adults)	0.27 - 5.50
PREGNANCY	
1st Trimester	0.10 - 3.00
2nd Trimester	0.20 - 3.00
3rd Trimester	0.30 - 4.10

NOTE:-TSH levels are subjected to circardian variation, reaching peak levels between 2-4 a.m and at a minimum between 6-10 pm. The variation is of the order of 50 %. Hence time of the day has influence on the measured serum TSH concentration.

USE: TSH controls biosynthesis and release of thyroid harmones T4 & T3. It is a sensitive measure of thyroid function, especially useful in early or subclinical hypothyroidism, before the patient develops any clinical findings or goitre or any other thyroid function abnormality.

INCREASED LEVELS:

- 1. Primary or untreated hypothyroidism, may vary from 3 times to more than 100 times normal depending on degree of hypofunction.
- 2. Hypothyroid patients receiving insufficient thyroid replacement therapy.
- 3. Hashimotos thyroiditis.
- 4.DRUGS: Amphetamines, Iodine containing agents and dopamine antagonist.
- 5. Neonatal period, increase in 1st 2-3 days of life due to post-natal surge.

DECREASED LEVELS:

- 1. Toxic multi-nodular goitre & Thyroiditis.
- 2. Over replacement of thyroid harmone in treatment of hypothyroidism.
- 3. Autonomously functioning Thyroid adenoma
- 4. Secondary pituatary or hypothalmic hypothyroidism
- 5. Acute psychiatric illness
- 6. Severe dehydration.
- 7.DRUGS: Glucocorticoids, Dopamine, Levodopa, T4 replacement therapy, Anti-thyroid drugs for thyrotoxicosis.



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)





A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

NAME : Mrs. RIYA GOEL

AGE/ GENDER : 27 YRS/FEMALE **PATIENT ID** : 1678192

COLLECTED BY REG. NO./LAB NO. : 122411210016

REFERRED BY **REGISTRATION DATE** : 21/Nov/2024 02:20 PM BARCODE NO. : 12505769 **COLLECTION DATE** : 21/Nov/2024 03:14PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 21/Nov/2024 05:22PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit **Biological Reference interval**

8. Pregnancy: 1st and 2nd Trimester LIMITATIONS:

1.TSH may be normal in central hypothyroidism, recent rapid correction of hyperthyroidism or hypothyroidism, pregnancy, phenytoin therapy.

2. Autoimmune disorders may produce spurious results.

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)



A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

NAME : Mrs. RIYA GOEL

AGE/ GENDER : 27 YRS/FEMALE **PATIENT ID** : 1678192

COLLECTED BY REG. NO./LAB NO. : 122411210016

REFERRED BY **REGISTRATION DATE** : 21/Nov/2024 02:20 PM BARCODE NO. : 12505769 **COLLECTION DATE** : 21/Nov/2024 03:14PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 21/Nov/2024 05:22PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Value Unit **Biological Reference interval Test Name**

LUTEINISING HORMONE (LH)

LUTEINISING HORMONE (LH): SERUM mIU/mL MALES: 0.57 - 12.07

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY) FOLLICULAR PHASE: 1.80 -

11.78

MID-CYCLE PEAK: 7.59 - 89.08 LUTEAL PHASE: 0.56 - 14.0 POST MENOPAUSAL WITHOUT

HRT: 5.16 - 61.99

INTERPRETATION:

1. Luteinizing hormone (LH) is a glycoprotein hormone consisting of 2 non covalently bound subunits (alpha and beta). Gonadotropin-releasing hormone from the hypothalamus controls the secretion of the gonadotropins, FSH and LH, from the anterior pituitary.

2. In both males and females, LH is essential for reproduction. In females, the menstrual cycle is divided by a mid cycle surge of both LH and FSH into a follicular phase and a luteal phase.

3. This "LH surge" triggers ovulation thereby not only releasing the egg, but also initiating the conversion of the residual follicle into a corpus luteum that, in turn, produces progesterone to prepare the endometrium for a possiblei mplantation.

4. LH supports thecal cells in the ovary that provide androgens and hormonal precursors for estradiol production. LH in males acts on testicular interstitial cells of Leydig to cause increased synthesis of testosterone.

The test is useful in the following situations:

1. An adjunction the ovaluation of monetrial irregularities.

- 1. An adjunctin the evaluation of menstrual irregularities.
- 2. Evaluating patients with suspected hypogonadism
- 3. Predicting ovulation & Evaluating infertility
- 4. Diagnosing pituitary disorders
- 5. In both males and females, primary hypogonadism results in an elevation of basal follicle-stimulating hormone and luteinizing hormone levels

FSH AND LH ELEVTED IN:

- 1. Primary gonadal failure
- 2. Complete testicular feminization syndrome
- 3. Precocious puberty (either idiopathic or secondary to a central nervous system lesion)
- 4. Menopause
- 5. Primary ovarian hypo dysfunction in females
- 6. Polycystic ovary disease in females
- 7. Primary hypogonadism in males

LH IS DECŘEÁSEĎ IN:

- 1. Primary ovarian hyper function in females
- Primary hypergonadism in males

1.FSH and LH are both decreased in failure of the pituitary or hypothalamus.

CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)



A PIONEER DIAGNOSTIC CENTRE

NAME : Mrs. RIYA GOEL

AGE/ GENDER : 27 YRS/FEMALE **PATIENT ID** : 1678192

COLLECTED BY REG. NO./LAB NO. : 122411210016

REFERRED BY **REGISTRATION DATE** : 21/Nov/2024 02:20 PM BARCODE NO. : 12505769 **COLLECTION DATE** : 21/Nov/2024 03:14PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

: P.K.R JAIN HEALTHCARE INSTITUTE

Value Unit **Biological Reference interval Test Name**

REPORTING DATE

FOLLICLE STIMULATING HORMONE (FSH)

FOLLICLE STIMULATING HORMONE (FSH): SERUM mIU/mL FEMALE FOLLICULAR PHASE:

by CLIA (CHEMILUMINESCENCE IMMUNOASSAY) 3.03 - 8.08

> FEMALE MID-CYCLE PEAK: 2.55 - 16.69

FEAMLE LUTEAL PHASE: 1.38 -

: 21/Nov/2024 05:22PM

5.47

FEMALE POST-MENOPAUSAL:

26.72 - 133.41 MALE: 0.95 - 11.95

INTERPRETATION:

CLIENT CODE.

1. Gonadotropin-releasing hormone from the hypothalamus controls the secretion of the gonadotropins, follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary.

2. The menstrual cycle is divided by a midcycle surge of both FSH and LH into a follicular phase and a luteal phase.

3. FSH appears to control gametogenesis in both males and females.

The test is useful in the following settings:

- 1. An adjunct in the evaluation of menstrual irregularities.
- Evaluating patients with suspected hypogonadism.
- 3. Predicting ovulation4. Evaluating infertility
- 5. Diagnosing pituitary disorders
- 6. In both males and females, primary hypogonadism results in an elevation of basal follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels

FSH and LH LEVELS ELEVATED IN:

- Primary gonadal failure
 Complete testicular feminization syndrome.
- 3. Precocious puberty (either idiopathic or secondary to a central nervous system lesion) 4. Menopause (postmenopausal FSH levels are generally >40 IU/L)
- 5. Primary ovarian hypofunction in females
- 6. Primary hypogonadism in males

1. Normal or decreased FSH is seen in polycystic ovarian disease in females 2. FSH and LH are both decreased in failure of the pituitary or hypothalamus.

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)







A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 pkrjainhealthcare@gmail.com

NAME : Mrs. RIYA GOEL

AGE/ GENDER : 27 YRS/FEMALE **PATIENT ID** : 1678192

COLLECTED BY REG. NO./LAB NO. : 122411210016

REFERRED BY **REGISTRATION DATE** : 21/Nov/2024 02:20 PM BARCODE NO. : 12505769 **COLLECTION DATE** : 21/Nov/2024 03:14PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 21/Nov/2024 05:22PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Value Unit **Biological Reference interval Test Name**

PROLACTIN

PROLACTIN: SERUM 24.07 ng/mL 3 - 25

by CMIA (CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY)

1. Prolactin is secreted by the anterior pituitary gland and controlled by the hypothalamus.
2. The major chemical controlling prolactin secretion is dopamine, which inhibits prolactin secretion from the pituitary.

3. Physiological function of prolactin is the stimulation of milk production. In normal individuals, the prolactin level rises in response to physiologic stimuli such as sleep, exercise, nipple stimulation, sexual intercourse, hypoglycemia, postpartum period, and also is elevated in the newborn infant.

INCREASED (HYPERPROLACTEMIA):

- 1.Prolactin-secreting pituitary adenoma (prolactinoma, which is 5 times more frequent in females than males). 2.Functional and organic disease of the hypothalamus.
- 3. Primary hypothyroidism.
- 4. Section compression of the pituitary stalk.
- 5. Chest wall lesions and renal failure.
- 6. Ectopic tumors
- 7.DRUGS:- Anti-Dopaminergic drugs like antipsychotic drugs, antinausea/antiemetic drugs, Drugs that affect CNS serotonin metabolism, serotonin receptors, or serotonin reuptake (anti-depressants of all classes, ergot derivatives, some illegal drugs such as cannabis), Antihypertensive drugs ,Opiates, High doses of estrogen or progesterone,anticonvulsants (valporic acid), anti-tuberculous medications (Isoniazid). SIGNIFICANCE:
- 1. In loss of libido, galactorrhea, oligomHyperprolactinemia often results enorrhea or amenorrhea, and infertility in premenopausal females. 2. Loss of libido, impotence, infertility, and hypogonadism in males. Postmenopausal and premenopausal women, as well as men, can also suffer from decreased muscle mass and osteoporosis.

- 3. In males, prolactin levels >13 ng/mL are indicative of hyperprolactinemia.
 4. In women, prolactin levels >27 ng/mL in the absence of pregnancy and postpartum lactation are indicative of hyperprolactinemia.
 5. Clear symptoms and signs of hyperprolactinemia are often absent in patients with server prolactin levels <100 ng/mL.
 4. Miles to impresent to Measure levels of serum prolactin are not a reliable guide for determining whether a prolactin-producing pituitary adenoma is present, 5. Whereas levels >250 ng/mL are usually associated with a prolactin-secreting tumor. **CAUTION:**

Prolactin values that exceed the reference values may be due to macroprolactin (prolactin bound to immunoglobulin). Macroprolactin should be evaluated if signs and symptoms of hyperprolactinemia are absent, or pituitary imaging studies are not informative.

*** End Of Report ***



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

